Menu
Search
|

Menu

Close
X

Allena Pharmaceuticals Inc ALNA.OQ (NASDAQ Stock Exchange Global Select Market)

11.20 USD
-- (--)
As of Jul 16
chart
Previous Close 11.20
Open --
Volume --
3m Avg Volume 37,051
Today’s High --
Today’s Low --
52 Week High 17.55
52 Week Low 6.15
Shares Outstanding (mil) 20.70
Market Capitalization (mil) 235.52
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.381
FY17
-1.053
FY16
-0.601
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.15
Price to Sales (TTM)
vs sector
--
8.04
Price to Book (MRQ)
vs sector
3.07
4.28
Price to Cash Flow (TTM)
vs sector
--
22.37
Total Debt to Equity (MRQ)
vs sector
11.15
17.43
LT Debt to Equity (MRQ)
vs sector
6.02
13.25
Return on Investment (TTM)
vs sector
--
13.23
Return on Equity (TTM)
vs sector
--
15.27

EXECUTIVE LEADERSHIP

Louis Brenner
President, Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Alexey Margolin
Chief Executive Officer, Co-Founder, Director, Since 2016
Salary: --
Bonus: --
Hugh Wight
Vice President - Technical Operations, Since
Salary: --
Bonus: --
Bob Tepper
Director, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 Newton Executive Park Ste 202
NEWTON   MA   02462-1435

Phone: +1617.4674577

Allena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.

SPONSORED STORIES